Key Highlights

  • Obsidian Therapeutics (NASDAQ:OBX) rose 5.16% pre-market after a 67% melanoma response rate, with a Market Value of USD 790 million and an RSI of 33.8, on 100 shares, on 100 shares, on 100 shares.
  • Patterson-UTI Energy (NASDAQ:PTEN) rose 3.62% pre-market as oil tops USD 100, with a market value of USD 4.32 billion and an RSI of 47.6, on 100 shares, on 100 shares, on 100 shares, on 100 shares.
  • Olema Pharmaceuticals (NASDAQ:OLMA) rose 4.76% pre-market after a Phase 3 delay, with a market value of USD 644 million and an RSI of 20.7, on 182 shares, on 182 shares, on 182 shares, on 182 shares.
  • OpenWorld (NASDAQ:OPNW) fell 4.77% pre-market after a Merger and rename, with a market value of USD 5 million and an RSI of 36.4, on 674 shares, on 674 shares, on 674 shares, on 674 shares.

Obsidian Therapeutics (NASDAQ:OBX): 67% Response, USD 350 Million Raised

Obsidian Therapeutics (NASDAQ:OBX) rose 5.16% pre-market to a listed USD 12.79 on 100 shares, with a market Capitalization of USD 790 million and an RSI of 33.8 labeled Down. Obsidian Therapeutics began trading on Nasdaq as OBX on August 4, 2026 after completing its merger with Galera Therapeutics alongside a USD 350 million private placement. Its lead program OBX-115, also called amsoki-cel, is a tumor-infiltrating lymphocyte therapy engineered with regulatable membrane-bound IL-15 that removes the need for toxic interleukin-2 dosing. OBX-115 holds FDA Fast Track and Regenerative Medicine Advanced Therapy designations, and a Phase 1 lung cancer trial has shown multiple confirmed partial responses. Cash of about USD 350 million after the deal compares with a USD 790 million market value, and the 52-week range runs from USD 4.30 to USD 49.97. Cell therapy manufacturing, small sample sizes and a recent merger listing add execution risk, and a 100-share print says nothing about demand. By market value it ranks 2 of 5 in this group. What to watch next: lung cancer Phase 1 data in 1H 2027 and the melanoma registration cohort.

Patterson-UTI Energy (NASDAQ:PTEN): Oil Above USD 100, Rigs Rising

Patterson-UTI Energy (NASDAQ:PTEN) rose 3.62% pre-market to a listed USD 11.33 on 100 shares, with a market capitalization of USD 4.32 billion and an RSI of 47.6 labeled Mixed. Patterson-UTI reported second-quarter 2026 Revenue of USD 1.228 billion, a 10% sequential increase, with Completion Services revenue of USD 754 million and adjusted Gross Profit of USD 123 million. Drilling Services revenue was USD 374 million, Drilling Products revenue was USD 91 million, its highest since the Ulterra acquisition, and completion pricing rose on near-full utilization. Adjusted EBITDA was USD 232 million, adjusted Net Income was USD 1 million, and net loss attributable to common stockholders was USD 20 million. Management guided about 100 rigs for the third quarter, Drilling Services adjusted gross profit near USD 145 million and Completion Services near USD 140 million, with 2026 capital spending around USD 600 million. Oil price reversals, a peace deal or weaker rig Demand would hit activity, and a 100-share print is not a reliable signal. By market value it ranks 1 of 5 in this group. What to watch next: oil prices, the rig count and third-quarter results.

Olema Pharmaceuticals (NASDAQ:OLMA): Phase 3 Pushed to 2027

Olema Pharmaceuticals (NASDAQ:OLMA) rose 4.76% pre-market to a listed USD 7.36 on 182 shares, with a market capitalization of USD 644 million and an RSI of 20.7 labeled Down, oversold. Olema reported on August 10 that enrollment in the pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in second- and third-line ER-positive, HER2-negative metastatic breast cancer was complete. The top-line readout, previously expected in fall 2026, is now expected in the first quarter of 2027, which pushes the key catalyst out by several months. Cash, cash equivalents and marketable securities were USD 461.1 million at June 30, down from USD 505.3 million at March 31, a drop of USD 44.2 million in one quarter. The net loss widened to USD 63.2 million from USD 43.8 million as late-stage trial spending rose, and the market value of USD 644 million is about 1.4 times cash. A binary Phase 3 outcome in 2027 and rising spending keep the stock volatile, and an oversold RSI does not predict a rebound. By market value it ranks 3 of 5 in this group. What to watch next: the OPERA-01 top-line data and quarterly cash burn.

OpenWorld (NASDAQ:OPNW): VerifyMe Merger Completes

OpenWorld (NASDAQ:OPNW) fell 4.77% pre-market to a listed USD 3.98 on 674 shares, with a market capitalization of USD 5 million and an RSI of 36.4 labeled Down. OpenWorld and VerifyMe completed their Business combination, and the combined company changed its name to OpenWorld, Inc. with its stock trading as OPNW from the open on October 1, 2026. OpenWorld describes itself as a real-world asset tokenization company that co-architects and takes principal positions in enterprise blockchain initiatives alongside governments, institutions and large enterprises. The company says it has advised on projects representing over USD 66 billion of aggregate network value since its 2023 founding and supported more than 20 companies backed by major venture firms. Figure OPEN is expected to be live by November 2026, so dual listing timing falls within weeks. A just-completed reverse merger, tokenization regulation and a very small market value make the stock highly speculative. By market value it ranks 5 of 5 in this group. What to watch next: the Blocksight deal, the Figure OPEN listing and financing.

Designer Brands (NYSE:DBI): Guidance Raised, Comps Negative

Designer Brands (NYSE:DBI) rose 5.16% pre-market to a listed USD 5.81 on 389 shares, with a market capitalization of USD 297 million and an RSI of 45.5 labeled Down. Designer Brands reported second-quarter 2026 results on September 10, with net sales of USD 730.6 million, down 1.2%, comparable sales down 2.4% and net income of USD 17.6 million, or USD 0.31 per diluted share. Adjusted diluted EPS of USD 0.34 beat the USD 0.26 consensus, while revenue of USD 730.6 million missed expectations by about USD 14 million. Total Debt was USD 423.1 million versus USD 516.3 million a year earlier, and inventories were USD 594.7 million versus USD 610.9 million. Adjusted Operating Income was USD 39.4 million with a 140 basis point improvement in margin, and the guidance assumes an effective tax rate near 41% and about 57 million diluted shares. Tariff refunds flatter margins, third-quarter profit pressure was flagged, and comparable store sales are still negative. By market value it ranks 4 of 5 in this group. What to watch next: third-quarter results and tariff refund timing.

Where Things Stand

Five stocks moved on fewer than 700 shares each, which means the displayed percentages describe a handful of trades. Obsidian Therapeutics (NASDAQ:OBX) rose 5.16%. Patterson-UTI Energy (NASDAQ:PTEN) rose 3.62%. Olema Pharmaceuticals (NASDAQ:OLMA) rose 4.76%. OpenWorld (NASDAQ:OPNW) fell 4.77%. Designer Brands (NYSE:DBI) rose 5.16%. Pre-market moves on thin Volume often reverse, so the balance of evidence favors waiting for the open and for filings. Direction remains unknown, and each name carries its own risks. Verify the latest filings before acting, and treat the figures as a snapshot.